Skip to main content

CORRECTION article

Front. Lupus, 04 June 2024
Sec. Clinical Research and Treatment in Lupus
Volume 2 - 2024 | https://doi.org/10.3389/flupu.2024.1432884

Corrigendum: Microfibrillar-associated protein 4 interaction with inflammation and clinical characteristics in neuropsychiatric systemic lupus erythematosus

This article is a correction to:

  1. Microfibrillar-associated protein 4 interaction with inflammation and clinical characteristics in neuropsychiatric systemic lupus erythematosus

    1. Read original article
\r\nMaria Alexandra Bandehkhoda Wegener,Maria Alexandra Bandehkhoda Wegener1,2Sren Mller,Sören Möller3,4Mads Nikolaj Olesen,,,,&#x;Mads Nikolaj Olesen1,2,5,6,†Jonna Skov Madsen,Jonna Skov Madsen2,7Grith Lykke Sorensen,,Grith Lykke Sorensen5,6,8Anne Voss,,Anne Voss3,9,10Nasrin Asgari,,, \r\nNasrin Asgari1,2,3,5*
  • 1Department of Neurology, Slagelse Hospital, Slagelse, Denmark
  • 2Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark
  • 3Open Patient Data Explorative Network, Odense University Hospital & Research Unit OPEN, Odense, Denmark
  • 4The Department of Clinical Research, University of Southern Denmark, Odense, Denmark
  • 5Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
  • 6The Department of Clinical Immunology, Odense University Hospital, Odense, Denmark
  • 7Department of Clinical Biochemistry and Immunology, Lillebaelt Hospital, Vejle, Denmark
  • 8Cancer and Inflammation Research, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
  • 9Department of Rheumatology, Odense University Hospital, Odense, Denmark
  • 10Research Unit of Rheumatology, University of Southern Denmark, Odense, Denmark

A Corrigendum on

Microfibrillar-associated protein 4 interaction with inflammation and clinical characteristics in neuropsychiatric systemic lupus erythematosus

Wegener MAB, Möller Sören, Olesen MN, Madsen JS, Sorensen GL, Voss A and Asgari N (2024). Front. Lupus 2:1386256. doi: 10.3389/flupu.2024.1386256

In the published article, there was an error. “Data not shown” should have been deleted. A correction has been made to 3 Results, 3.5 Markers of BBB disruption. This sentence previously stated:

“Additionally, MMP-2 was significantly elevated in NPSLE patients with CNS manifestations compared to PNS manifestations (p = 0.010, data not shown).”

The corrected sentence appears below:

“Additionally, MMP-2 was significantly elevated in NPSLE patients with CNS manifestations compared to PNS manifestations (p = 0.010).”

In the published article, there was an error. The below sentences in the Discussion should have been deleted. A correction has been made to the 4 Discussion. The below sentences have been removed:

“Interestingly, MFAP4 was associated with SLICC (accumulated disease damage) in the total SLE cohort suggesting that MFAP4 may reflect inflammation. Interestingly, MFAP4 was associated with SLICC in the total SLE cohort suggesting that MFAP4 may reflect inflammation.”

In the published article, there was an error in the punctuation of the of caption Figure 4. The corrected legend appears below.

Figure 4. Correlation of MFAP4 with MMP-7 and VEGF in NPSLE subgroup and non-NPSLE subgroup. A significant association was found between MMP-7 and MFAP4 within NPSLE patients (A). Likewise, a significant association was found between VEGF and MFAP4 within NPSLE patients (C). No association was found between MMP-7 and MFAP4 (B) nor between VEGF and MFAP4 (D) in the non-NPSLE subgroup. Grey zone, confidence band. MFAP4, microfibrillar-associated protein 4; MMP-7, matrix metalloproteinase 7; VEGF, vascular endothelial growth factor; SLE, systemic lupus erythematosus; NPSLE, neuropsychiatric systemic lupus erythematosus.

The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: systemic lupus erythematosus, neuropsychiatric SLE, inflammation, microfibrillar-associated protein 4, accumulated disease damage

Citation: Wegener MAB, Möller S, Olesen MN, Madsen JS, Sorensen GL, Voss A and Asgari N (2024) Corrigendum: Microfibrillar-associated protein 4 interaction with inflammation and clinical characteristics in neuropsychiatric systemic lupus erythematosus. Front. Lupus 2:1432884. doi: 10.3389/flupu.2024.1432884

Received: 14 May 2024; Accepted: 27 May 2024;
Published: 4 June 2024.

Edited and Reviewed by: Luís Pedro Sousa Inês, Coimbra Hospital and University Center, Portugal

© 2024 Wegener, Möller, Olesen, Madsen, Sorensen, Voss and Asgari. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Nasrin Asgari, nasgari@health.sdu.dk

†Present Addresses: Mads Nikolaj Olesen,Lundbeck A/S, Copenhagen, Denmark

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.